ArticleBMC cancer2025

Efficacy and safety of triplet regimen capecitabine, oxaliplatin, and irinotecan (XELOXIRI) as first-line chemotherapy for advanced pancreatic cancer.

Bi-Yang Cao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.